Ingestible Sensor MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy End UserBy ComponentBy Age Group

An ingestible sensor is a swallowable capsule or pill-sized device that carries a miniaturized sensing element, such as an imaging chip, a pressure or pH transducer, or a temperature-sensing circuit, through the gastrointestinal tract while transmitting or recording physiological data to an external receiver. The category spans single-use diagnostic capsules used for endoscopy and motility testing, reusable core-temperature monitors used in occupational and athletic settings, and adherence-tracking sensors embedded in a prescribed medication. Buyers include hospitals and gastroenterology clinics ordering a diagnostic procedure, sports medicine and physiology programs monitoring core temperature under exertion, and pharmaceutical or care-management programs seeking objective confirmation that a medication was taken.

Growth of 12% a year carries the global ingestible sensor market from USD 1.18 billion in 2025 to USD 3.343 billion in 2034. The full series behind that rate covers USD 0.62 billion in 2020, USD 1.041 billion in 2024, USD 1.35 billion in 2026 and USD 2.124 billion in 2030, with 2025 as the base year.

49.15% of 2025 revenue sits in Image sensor, worth USD 0.58 billion and rising to USD 1.471 billion at 44% by 2034, the largest type line in both years. Growth is fastest in Pressure sensor at 13.4% and slowest in Image sensor at 10.6%. Share moves toward Pressure sensor, pH sensor and Temperature sensor and away from Image sensor, though no line shrinks in revenue terms.

By application, Medical/healthcare accounts for 83.98% of 2025 revenue at USD 0.991 billion, reaching USD 2.674 billion and 79.99% by 2034. Sports & fitness grows faster at 16.5% against 11.7%, moving from 10% of revenue to 14% by 2034. This axis divides the same revenue as the type split instead of adding to it, so the two are read together and never summed.

USD 0.448 billion of 2025 revenue is generated in North America, 38% of the global total and the largest regional share; it reaches USD 1.137 billion by 2034. Europe is next at 27% and USD 0.319 billion, and Middle East and Africa last at 5%. Because Asia Pacific take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Coverage extends to five regions, four type lines and five segmentation axes over the full fifteen years. The 2025 total itself is a triangulation of published figures and category proxies, short of a directly sourced total, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global ingestible sensor market moves from USD 0.62 billion in 2020 to USD 1.18 billion in 2025 and USD 3.343 billion by 2034, the forecast period compounding at 12% a year.
• The largest line by type is Image sensor, worth USD 0.58 billion and 49.15% of revenue in 2025, rising to USD 1.471 billion and 44% by 2034.
• Fastest growth on the type axis belongs to Pressure sensor: 13.4% a year, USD 0.253 billion to USD 0.802 billion, and a share moving from 21.44% to 23.99%.
• Against a base case of USD 3.343 billion in 2034, the study also reports a bear case at USD 2.875 billion and a bull case at USD 3.811 billion, with the assumptions behind each set out separately.
• 38% of 2025 revenue is generated in North America, worth USD 0.448 billion and rising to USD 1.137 billion by 2034; Middle East and Africa is smallest at 5%.
• 83.9% of North America's base-year revenue comes from the United States alone: USD 0.376 billion in 2025, rising to USD 0.944 billion by 2034, which is why it is that region's worked example.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 12% compounding underneath both.

None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.

The type mix tilts toward Pressure sensor. The widest spread on the type axis is between Pressure sensor at 13.4% and Image sensor at 10.6%. Pressure sensor takes its share of revenue from 21.44% to 23.99% while Image sensor gives up ground, from 49.15% to 44%. The revenue figures behind that are USD 0.253 billion to USD 0.802 billion and USD 0.58 billion to USD 1.471 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific. Asia Pacific moves from 24% of revenue in 2025 to 31% in 2034, worth USD 0.283 billion rising to USD 1.036 billion. Against that, North America at 38% moving to 34%, Europe at 27% moving to 24%, Latin America at 6% moving to 6%, Middle East and Africa at 5% moving to 5%, a fall in share, not in revenue. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

Growth compounds at 12% without a step change. Year by year the total runs USD 0.62 billion in 2020, USD 1.041 billion in 2024, USD 1.18 billion in 2025, USD 1.35 billion in 2026, USD 2.124 billion in 2030 and USD 3.343 billion in 2034. Against 13.7% through the historical period, the 12% forecast rate is a continuation; no year in the series interrupts it. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the type and regional sections come in.

Growth is concentrated in Pressure sensor

Growth in the global ingestible sensor market comes from three measurable sources over 2026-2034: the market's own compounding at 12%, the share gained by faster-growing type lines, and expansion in the regions taking a larger part of global revenue.

What holds the forecast back

Upside case: USD 3.811 billion by 2034

One type line carries the market

North America holds 38% of the global ingestible sensor market in 2025, worth USD 0.448 billion with USD 1.137 billion projected for 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

34% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Image sensor largest at 49.15% of 2025 revenue, Pressure sensor fastest at 13.4%. North America is reported axis by axis and country by country in the full study.

The United States is the largest market within North America, generating USD 0.376 billion in 2025 and projected to reach USD 0.944 billion by 2034. Because it is 83.9% of the region in the base year, North America's totals move with this one country instead of a spread of them. Set against USD 0.448 billion and USD 1.137 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Demand in the United States follows the type mix reported at global level: Image sensor is the largest line at 49.15% of 2025 revenue, moving to 44% by 2034, while Pressure sensor grows fastest at 13.4% and takes its share from 21.44% to 23.99%. Because the country carries 83.9% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The United States carries its own type breakdown in the full report.

Ingestible sensors fall under the Food and Drug Administration's jurisdiction, and because the technology is typically paired with a drug product to confirm dosing or adherence, it is usually reviewed as a combination product spanning the device and drug centers. The device component is classified according to the risk it poses and generally proceeds through a premarket clearance pathway that requires the maker to demonstrate the sensor performs as intended and communicates safely with any receiver or app. Manufacturing must follow the agency's quality system requirements, and labeling must clearly state the product's intended use, its ingestion instructions, and any warnings tied to the paired medication. Ongoing adverse event reporting applies once the product reaches the market.

The suppliers tracked in this study (HQ, Inc, Proteus Digital Health, Inc., CapsoVision, Inc, Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, MC10, DAR&Eacute, BIOSCIENCE, Oracle and Atmo Biosciences, JINSHAN Science & Technology and and others.) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Image sensor at 49.15% of 2025 revenue, and taking Pressure sensor while it grows at 13.4%. Per-company positioning and share at country level are in the full report only.

5.7% of global revenue is generated in Canada; USD 0.067 billion in 2025, reaching USD 0.171 billion in 2034, and 15% of North America.

Europe holds 27% of the global ingestible sensor market in 2025, worth USD 0.319 billion and reaches USD 0.802 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 24% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Image sensor leads here as it does globally, at 49.15% of 2025 revenue, and Pressure sensor again grows fastest at 13.4%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

30.1% of Europe's base-year revenue comes from Germany; USD 0.096 billion, rising to USD 0.225 billion by 2034. 30.1% of the region in the base year makes it the largest market here without making it the region. Set against USD 0.319 billion and USD 0.802 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Image sensor first at 49.15% of 2025 revenue and 44% in 2034, Pressure sensor fastest at 13.4% on a share moving from 21.44% to 23.99%. With 30.1% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Germany by type separately.

As an EU member state, Germany applies the Medical Device Regulation to ingestible sensors, treating them as electronic devices intended for physiological monitoring once swallowed. A manufacturer must run the product through a conformity assessment with a notified body before affixing the CE mark, with the depth of scrutiny set by the device's risk classification. The Federal Institute for Drugs and Medical Devices acts as the competent national authority and receives incident reports once the sensor is in use. Technical documentation must show conformity with harmonized standards covering electrical safety, biocompatibility of any ingested casing, and data handling, and labeling must be provided in German alongside clear instructions for patients and clinicians.

In Germany the field is HQ, Inc, Proteus Digital Health, Inc., CapsoVision, Inc, Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, MC10, DAR&Eacute, BIOSCIENCE, Oracle and Atmo Biosciences, JINSHAN Science & Technology and and others.. Image sensor, at 49.15% of 2025 revenue, is where the volume sits, and Pressure sensor, growing at 13.4%, is where position changes hands over the forecast period. That makes Europe a 27% share of 2025 global revenue, USD 0.319 billion rising to USD 0.802 billion, for any supplier deciding where to concentrate.

The United Kingdom is sized at USD 0.083 billion in 2025, rising to USD 0.201 billion by 2034; 7% of global revenue and 26% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

France is sized at USD 0.057 billion in 2025, rising to USD 0.136 billion by 2034; 4.8% of global revenue and 17.9% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

USD 0.283 billion of 2025 revenue is generated in Asia Pacific, 24% of the global ingestible sensor market rising to USD 1.036 billion in 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 31% over the forecast period, so the region grows faster than the market's 12% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Image sensor largest at 49.15% of 2025 revenue, Pressure sensor fastest at 13.4%. Per-axis and per-country detail for Asia Pacific sits in the full report.

Japan is the largest market within Asia Pacific, generating USD 0.096 billion in 2025 and projected to reach USD 0.29 billion by 2034. At 33.9% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. The region itself runs USD 0.283 billion to USD 1.036 billion over the same period, and this is the market carrying the country-level detail in the full report.

Japan buys along the same lines as the market globally; Image sensor first at 49.15% of 2025 revenue and 44% in 2034, Pressure sensor fastest at 13.4% on a share moving from 21.44% to 23.99%. Its 33.9% weight in Asia Pacific means those movements carry straight into the regional totals. The full report reports Japan by type separately.

Ingestible sensors are regulated under the Act on Pharmaceuticals and Medical Devices, with the Pharmaceuticals and Medical Devices Agency conducting the technical review that feeds into the health ministry's approval decision. Because the sensor is swallowed and often linked to medication adherence, reviewers examine both the electronic component's safety and, where a drug is co-packaged, the combination's overall risk profile. A supplier must classify the product correctly, submit performance and safety data suited to that classification, and obtain approval before marketing. Labeling must be rendered in Japanese, disclose the device's intended use and ingestion method, and a quality management system covering manufacturing and post-market surveillance is expected to stay in place after launch.

The suppliers tracked in this study (HQ, Inc, Proteus Digital Health, Inc., CapsoVision, Inc, Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, MC10, DAR&Eacute, BIOSCIENCE, Oracle and Atmo Biosciences, JINSHAN Science & Technology and and others.) compete in Japan across the type lines above. The commercially relevant division is 49.15% of 2025 revenue in Image sensor, where the volume is, against 13.4% growth in Pressure sensor, where share moves. That makes Asia Pacific a 24% share of 2025 global revenue, USD 0.283 billion rising to USD 1.036 billion, for any supplier deciding where to concentrate.

Within Asia Pacific, China accounts for 30% of regional revenue and 7.2% of the global total, worth USD 0.085 billion in 2025 and USD 0.373 billion by 2034.

Within Asia Pacific, India accounts for 14.1% of regional revenue and 3.4% of the global total, worth USD 0.04 billion in 2025 and USD 0.186 billion by 2034.

USD 0.071 billion of 2025 revenue is generated in Latin America, 6% of the global ingestible sensor market on the way to USD 0.201 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

By 2034 the share stands at 6%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the type split tracks the global one; 49.15% of 2025 revenue in Image sensor, fastest growth of 13.4% in Pressure sensor. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 0.039 billion in 2025 and USD 0.107 billion in 2034. Its 54.9% of base-year regional revenue leads the region, though enough sits elsewhere that Latin America is not a proxy for it. Regional revenue of USD 0.071 billion in 2025 and USD 0.201 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Brazil buys along the same lines as the market globally; Image sensor first at 49.15% of 2025 revenue and 44% in 2034, Pressure sensor fastest at 13.4% on a share moving from 21.44% to 23.99%. With 54.9% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Brazil carries its own type breakdown in the full report.

Brazil's health surveillance agency, ANVISA, governs ingestible sensors as medical devices and requires registration before a product can be marketed. The applicant must classify the device according to the risk it presents, since an implantable-adjacent or ingested electronic component intended to monitor the body typically draws closer scrutiny than a simple external monitor. Registration dossiers must include safety and performance evidence, and manufacturing sites are expected to conform to Brazil's own good manufacturing practice requirements, which ANVISA verifies through inspection. Labeling and instructions for use must appear in Portuguese and describe the ingestion method, intended use, and any warnings tied to the sensor's operation, and post-market vigilance obligations continue once the device is sold.

In Brazil the field is HQ, Inc, Proteus Digital Health, Inc., CapsoVision, Inc, Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, MC10, DAR&Eacute, BIOSCIENCE, Oracle and Atmo Biosciences, JINSHAN Science & Technology and and others.. Two different problems sit on the same axis: holding Image sensor at 49.15% of 2025 revenue, and taking Pressure sensor while it grows at 13.4%. Weighting toward Latin America means competing for 6% of 2025 global revenue, a base of USD 0.071 billion moving to USD 0.201 billion across the forecast period.

1.7% of global revenue is generated in Mexico; USD 0.02 billion in 2025, reaching USD 0.058 billion in 2034, and 28.2% of Latin America.

5% of the global ingestible sensor market sits in Middle East and Africa in 2025, worth USD 0.059 billion rising to USD 0.167 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

Share settles at 5% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Image sensor leads here as it does globally, at 49.15% of 2025 revenue, and Pressure sensor again grows fastest at 13.4%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.021 billion in 2025 and projected to reach USD 0.058 billion by 2034. At 35.6% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Set against USD 0.059 billion and USD 0.167 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Image sensor at 49.15% of 2025 revenue, easing to 44% by 2034, and the fastest is Pressure sensor at 13.4%, from 21.44% to 23.99%. Its 35.6% weight in Middle East and Africa means those movements carry straight into the regional totals. Saudi Arabia carries its own type breakdown in the full report.

The Saudi Food and Drug Authority oversees ingestible sensors as medical devices, and a supplier must register the product through the authority's medical device bureau before it can be sold in the kingdom. The classification route follows a risk-based system aligned with international medical device frameworks, so the sensor's category determines the depth of technical documentation and conformity evidence required. Manufacturers must show the device meets relevant safety and performance standards, often relying on conformity already established with a recognized foreign regulator as supporting evidence. Labeling must be provided in Arabic, state the intended use and ingestion instructions clearly, and importers are expected to maintain a local authorized representative for ongoing regulatory contact and vigilance reporting.

In Saudi Arabia the field is HQ, Inc, Proteus Digital Health, Inc., CapsoVision, Inc, Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, MC10, DAR&Eacute, BIOSCIENCE, Oracle and Atmo Biosciences, JINSHAN Science & Technology and and others.. Two different problems sit on the same axis: holding Image sensor at 49.15% of 2025 revenue, and taking Pressure sensor while it grows at 13.4%. The commercial size of that position is USD 0.059 billion in 2025 and USD 0.167 billion by 2034, 5% of the global total in the base year.

Within Middle East and Africa, South Africa accounts for 22% of regional revenue and 1.1% of the global total, worth USD 0.013 billion in 2025 and USD 0.037 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, end user, component, age group, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.